CDSCO bans HealthCare Global’s ethics panel, halting new trials for two years
India's drug regulator CDSCO has barred the Ethics Committee of HealthCare Global Enterprises for two years, halting all new clinical trials at its Bengaluru cancer institute. The ban follows uncovered deaths and undisclosed adverse events between 2021‑2025, and the hospital must compensate victims' families. This sidelines a KKR‑backed hospital chain from a key growth engine.